DCLK1 expression is particularly relevant in pancreatic ductal adenocarcinoma (PDAC), where its high expression correlates negatively with PDAC patients’ lifespan.160 Ferguson et al. worked on the development and characterization of DCLK1-IN-1 inhibitors. Here, DCLK1 is linked to pancreatic ductal adenocarcinoma.